Alps Advisors Inc Aeglea Bio Therapeutics, Inc. Transaction History

Alps Advisors Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.5 - $2.66 $25,367 - $134,955	-50,735 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.87 - $4.77 $11,865 - $30,265	-6,345 Reduced 11.12%	50,735 $117,000
Q4 2021 Feb 09, 2022	BUY	$3.5 - $8.42 $199,780 - $480,613	57,080 New	57,080 $271,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.